von Hippel-Lindau (VHL) mutation carriers develop benign and malignant tumours, requiring regular surveillance. The aim of this study was to calculate the optimal organ-specific age to initiate surveillance and optimal intervals to detect initial and subsequent VHL-related manifestations. In this study, we compare these results with the current VHL surveillance guidelines. We collected data from 82 VHL mutation carriers in the Dutch VHL surveillance program. The cumulative proportion of carriers diagnosed with a first VHL-related manifestation was estimated by the Kaplan-Meier method. The Poisson distribution model was used to calculate average time to detection of the first VHL-related manifestation and subsequent manifestations. We used this to calculate the optimal organ-specific age to initiate surveillance and the surveillance interval that results in a detection probability of 5%. The calculated organ-specific ages to initiate surveillance were 0 years (birth) for adrenal glands, 7 years for the retina, 14 years for the cerebellum, 15 years for the spinal cord, 16 years for pancreas, and 18 years for the kidneys. The calculated surveillance intervals were 4 years for the adrenal glands, biennially for the retina and pancreas, and annually for the cerebellum, spinal cord, and kidneys. Compared to current VHL guidelines, the calculated starting age of surveillance was 6 years later for the retina and 5 years earlier for adrenal glands. The surveillance intervals were two times longer for the retina and four times longer for the adrenal glands. To attain a 5% detection probability rate per organ, our mathematical model indicates that several modifications of current VHL surveillance guidelines should be considered.
iNTROduCTiON
von Hippel-Lindau (VHL) disease is an autosomal dominant disorder caused by a germline mutation in the VHL gene (1) . The estimated incidence of VHL disease is between one in 36 000 and one in 85 000 newborns, with a penetrance rate of almost 100% by age 75 years (2) . In 2008, 109 living VHL mutation carriers older than 15 years with VHL disease were identified in The Netherlands (3) .
VHL disease leads to the development of multiple vascularized lesions in the CNS. These CNS lesions include haemangioblastomas in the cerebellum, spinal cord, brain stem, nerve root, and supratentorial region; retinal angiomas; and endolymphatic sac tumours (ELST). Visceral features of VHL disease include renal cysts and renal cell cancers (RCC), pheochromocytomas, pancreatic cysts, and pancreatic neuroendocrine tumours (pNET), as well as epididymal and broad ligament cystadenomas (1, 4) .
VHL phenotypes are classified into two types based on clinical appearance: type 1 and type 2 (2a, 2b, and 2c). Type 1 includes all typical VHL-related manifestations except pheochromocytomas. Type 2a and 2b exhibit the full VHL-related manifestation spectrum with low (2a) and high (2b) risk for RCC, while type 2c carriers develop only pheochromocytoma (5) . The exact relationship between genotype and phenotype is still unknown (6) . Currently, the same surveillance schedules are used for all VHL phenotypes. Based on the occurrence of manifestations and their consequences, all VHL mutation carriers and first-degree relatives with unknown VHL gene status are offered surveillance consisting of regular follow-up visits for each organ involved in VHL disease. Work-up according to the Danish, US, and Dutch VHL surveillance guidelines includes biennial MRI for CNS, MRI/CT/ultrasound scans for visceral organs, and yearly ophthalmologist consultation (1-3, 7, 8) .
VHL surveillance according to the current Danish and US guidelines reduces VHL-related morbidity and mortality (2, 9, 10) . However, the age to start surveillance and the surveillance interval are based on limited evidence (2, 4, 7) . If the probabilities of developing VHL-related manifestations at various ages could be estimated, this would enable evidence-based decisions to be made on the age to start VHL surveillance and on the subsequent surveillance intervals. The aims of our study were, therefore, to calculate the organ-specific age to start surveillance, to calculate the surveillance intervals for detecting the first and subsequent VHL-related manifestations, and to compare these calculations with current VHL surveillance guidelines (2, 4, 7, 8) .
We based our approach on Knudson's 'second-hit' hypothesis, which is supported by evidence that VHL-related RCC and haemangioblastomas occur as a consequence of a mutation in the one healthy VHL gene (9, 10) . Predictive Poisson distribution models can then be used to express the probability of the detection of a VHL-related manifestation over time (11) . The linear regression of this Poisson distribution model can provide a calculated average number of years between a first hit and detection of the first VHL-related manifestation (δ) and an average number of years between two subsequent hits (time between hits, TBH).
SubjECTS ANd METHOdS

study population
Eligible individuals for this analysis were VHL mutation carriers who underwent VHL surveillance between 1972 and 2012 at two VHL expertise centers in The Netherlands: the University Medical Center Groningen and the University Medical Center Utrecht. A VHL mutation carrier was defined as an individual with a genetically confirmed VHL mutation or clinical VHL disease characterized by two or more CNS haemangioblastomas or a CNS haemangioblastoma(s) and visceral lesion(s) or by one typical VHL-related manifestation and a first-degree relative with genetically or clinically confirmed VHL disease (4).
Surveillance of VHL mutation carriers was performed according to the standard VHL surveillance guidelines in The Netherlands (www.stoet.nl, VHL working group), including the following If a lesion was found to increase in size, then imaging frequency was increased to 6-month intervals until stable disease was ascertained. If the carriers developed symptoms, interim surveillance examinations or specific imaging was performed. Surveillance for pheochromocytomas was performed annually by means of plasma and/or urinary concentrations of metanephrines (metanephrine and normetanephrine) (12) .
data collection procedures
We collected clinical data on VHL mutation carriers, covering the period 1959-2012, from electronic and written patient records. A computerized registration database is used to store data obtained from standard VHL surveillance; we retrieved all relevant data from this database and transferred those into a separate, anonymous database. The identity of the individuals was protected by unique codes, which were known only by two dedicated data managers. In case of uncertainties with respect to follow-up data, the larger databases could only be checked by the data manager, thereby assuring the protection of individual identity. Therefore, according to Dutch Medical Research Involving Human Subjects Act, no further Institutional Review Board approval was required.
Information on genealogy and on the affected family members of the carriers in the study was derived from reports of the Department of Clinical Genetics. Information obtained directly from individual patient records included date of birth, sex, the inherited or de novo mutation, and the organ-specific date of diagnosis of the first VHL-related manifestation (defined as organ involvement). When biochemical or clinical diagnosis of the manifestation preceded a diagnosis based on imaging reports, these data were used if confirmed during surveillance by ultrasound, CT, or MRI scan. The following manifestations were included: cerebral haemangioblastomas, spinal cord haemangioblastomas, retinal haemangioblastomas, RCC and renal cysts, pheochromocytoma, and pNETs and pancreatic cysts. Renal and pancreatic involvement was defined by its first manifestation, irrespective of pathological diagnosis (tumour or cyst). Data on the onset of renal and pancreatic manifestations of individuals born before 1965 and undergoing surveillance at the UMCG were not included because this group did not undergo abdominal surveillance until 1990. Otherwise, it would have appeared that a delay in detection of VHL-related manifestations had occurred, causing bias in this retrospective study. For additional analysis of the effect of VHL phenotype on the age of onset of VHL-related manifestations, the VHL mutation carriers were grouped according to VHL phenotype (type 1: all manifestations except pheochromocytoma; type 2a/b: full spectrum; and type 2c: pheochromocytoma only). Group assignment was based on the relevant literature and on the occurrence of a spectrum of VHL-related manifestations in their kindred or in their own history (13) (see Table 1 ). Kindreds developing only pheochromocytoma were regarded as type 2c (1 family). De novo VHL mutation carriers or VHL mutation carriers having a family history with diagnosis of pheochromocytoma and other VHL-related manifestations were defined as phenotype 2a/b. Carriers without diagnosis of pheochromocytoma in their personal or family history were defined as VHL phenotype 1 (13) .
statistical analysis
The aim of our study was not to test a hypothesis but to calculate Poisson parameters for time to detection of the first and subsequent VHL-related manifestations. Consequently, power analysis could not be performed. To indicate the precision of the calculations, we have shown the S.E..
Carriers of VHL phenotype 1 were excluded from all analyses for pheochromocytoma onset, as pheochromocytomas are not part of this phenotype. Carriers of VHL phenotype 2c were included for analyses of pheochromocytoma only, as this is their only manifestation.
The cumulative proportion of VHL mutation carriers during the entire life span with regard to age at time of detection of the first VHL-related manifestation was calculated by KaplanMeier method. Linear regression analysis of natural logarithm of 1-cumulative proportion (ln(1-cumulative proportion)) vs this age was carried out to estimate the average incidence κ (the hit rate) of tumour formation from the regression coefficient (=-κ). The average time between two subsequent hits (TBH) with its S.E. was derived from the inverse of κ and its S.E. (see Table 2 ). The average time between a first hit and detection of first VHL-related manifestation (delay=δ) was assessed from the intercept of the ln(1-cumulative proportion) with the age axis. The S.E. of δ was defined by the S.E. around the regression line divided by the regression coefficient κ. Cumulative proportions below the 5% level were excluded from the regression analysis because of the sloping edge caused by the variance of the delay. The cumulative proportions above age 65 years were also excluded from this analysis to prevent bias caused by mortality of patients.
The optimal age to start surveillance for each organ was calculated from the time to detection of the first manifestation (δ) -2 S.E., the lower end of the 95% CI of the estimated mean delay. So a safe lower boundary was established with a negligible risk of a first manifestation below this age of starting surveillance. The age of detection of the first VHL-related manifestation in VHL phenotype 1 carriers and in those with phenotype 2a/b were compared with log-rank tests.
The optimal surveillance interval for the detection of subsequent VHL-related manifestations was calculated for the 5, 10, and 20% proportion level of the TBH, defining the detection probability level roughly. Finally, the optimal VHL surveillance was defined by the 5% detection proportion to create a safe interval with a negligible risk to overlook a new manifestation.
The optimal age to stop surveillance in suspected carriers without known DNA status was defined as a probability of future development of a first VHL-related manifestation of <5% as calculated by the cumulative proportions of each organ. We added the cumulative proportions of retina, cerebellum, spinal cord, pancreas, and kidney manifestations during the entire life span to assess the number of affected organs per VHL mutation carrier. For this analysis, the carriers of phenotype 1 and 2a/b VHL disease were included. Adrenal gland manifestations were excluded from this analysis to guarantee that the maximum number of affected organs was comparable in both groups. The probability levels were calculated for two subgroups based on VHL phenotypes. Two-sided P values <0.05 were designated as statistically significant.
Comparison with VHL surveillance guidelines
The calculated age to start surveillance was compared with the currently advised starting age as defined by the Danish, Dutch, and US VHL surveillance guidelines (2, 3, 7, 8) . In addition, our calculated intervals for 5% detection probability were compared with the advised screening frequency in these same VHL surveillance guidelines.
RESuLTS
study population
We used data from 82 VHL mutation carriers in our study (see Fig. 1) , which is the majority of the 109 identified Dutch VHL mutation carriers. One male VHL mutation carrier was excluded from the analysis because he declined to undergo VHL surveillance. Characteristics of VHL mutation carriers (41 males and 41 females) are shown in Table 1 
Cumulative proportions and time to first and subsequent manifestations
At the age of 70 years, 63% of the VHL mutation carriers were diagnosed with pheochromocytoma, 73% with retinal angiomas, 77% with pancreas manifestations, 83% with spinal cord haemangioblastomas, 94% with cerebellar haemangioblastoma (see Fig. 2A ), and 99% with kidney manifestations (see Supplementary Figure 1 , see section on supplementary data given at the end of this article).
A linear relationship between ln(1-cumulative proportion) and age at first detection was found for all VHL-related manifestations (see Fig. 2B and Supplementary Figure 1) . The time between the first hit and the detection of first VHL-related manifestation ranged from 5.2 years for the adrenal glands (S.E. 4.42) to 23.6 years for the kidneys (S.E. 2.71) (see Table 2 ). The age at detection of the first kidney manifestation differed between VHL mutation carriers with phenotype 1 and carriers with phenotype 2a/b (P=0.028, Supplementary Table 1, see section on supplementary data given at the end of this article). The TBH ranged from 11.4 years for the kidneys (S.E. 1.14) to 73.3 years for the adrenal glands (S.E. 11.00).
Optimal surveillance for the detection of new VHL-related manifestations
The optimal age to start VHL surveillance ranged from 0 years for the adrenal glands to 18 years for the kidneys (see Table 2 ). The optimal VHL surveillance interval ranged from 0.57 years for the kidneys to 3.66 years for the adrenal glands (see Table 2 ). Compared to current VHL surveillance guidelines in Denmark, The Netherlands, and the USA (2, 3, 7, 8) , the calculated age to start surveillance was 6 years later for the retina, but 5 years earlier for the adrenal gland. Moreover, the calculated surveillance intervals were two times longer for the retina (2 years) and four times as long for the adrenal gland (4 years).
Probability of future development of VHL-related manifestation
According to the total cumulative proportion, four organs on average were affected at the age of 60 years in VHL mutation carriers of phenotypes 1 and 2a/b (see Fig. 3) . We calculated the age after which the probability offuture development of a first VHL-related manifestation was <5% (see Fig. 4 ). For VHL phenotypes 1 and 2a/b, we calculated that the probability of developing a first cerebral or spinal cord haemangioblastoma, retinal angioma, kidney cyst or tumour, or pancreatic cyst or tumour was <5% after the age of 34 years. For VHL phenotype 2c, the lifelong probability of developing a first pheochromocytoma was above 5% (see Fig. 4 ).
diSCuSSiON
This is the first study that has used Knudson's second-hit hypothesis in VHL mutation carriers to calculate time to detection of the first and subsequent VHL-related manifestations. This mathematical model provides a rationale to define the age to start surveillance and subsequent surveillance intervals, at an acceptable detection probability rate per organ. Compared to current Danish, Dutch, and US VHL surveillance guidelines, our calculations showed several deviations for the starting and stopping age of surveillance for various organs (2, 3, 7, 8) .
Surveillance guidelines in VHL will not be influenced by the specific inherited mutation as the second hit is random and is the depending factor in tumour onset. Surveillance guidelines in hereditary breast cancer and colon cancer and follow-up guidelines for melanoma are based on the probability levels of detecting a tumour at each surveillance visit (13) (14) (15) (16) (17) . These probability levels allow the definition of an acceptable percentage of new tumours that are missed during a defined interval. The surveillance interval is based on the consequences for a patient of a missed diagnosis, and by the sensitivity and specificity of the diagnostic method used. Therefore, we also used a pre-set detection probability level for calculating VHL surveillance intervals: the optimal VHL surveillance interval was set at 5% detection probability. This level is comparable to the detection rates for surveillance in breast and colon cancers (14, (16) (17) (18) .
Obviously, all calculated starting ages depend on the sensitivity of the detection methods used; more sensitive techniques could change our calculated age to start surveillance (19) (20) (21) .
Due to the substantial deviations from current guidelines in our calculations of the age to start surveillance and the subsequent surveillance intervals, we believe that the VHL surveillance guidelines should be adapted, especially for pheochromocytoma and retinal manifestations (2, 3, 7, 8) . The current surveillance guidelines recommend to start screening at 1 year of age for the retina, 5 years for the adrenal gland, and 16 years for the kidneys, pancreas, cerebellum, and spinal cord while our analyses support starting at 7 years of age for the retina and at birth for the adrenal gland. More recently, a recommendation for regular ELST surveillance was added to the VHL surveillance guidelines in the USA (8) . These ELST guidelines have not yet been incorporated into the VHL surveillance guidelines for The Netherlands.Therefore, the onset of ELST was not part of our study.
A substantial deviation from current VHL surveillance guidelines concerns our calculated age for starting retinal surveillance in VHL mutation carriers: at the age of 7 years, which is 6 years later than in the guidelines. Our findings are in line with the sparse literature on the onset of VHLrelated retinal angiomas, where detection before the age of 7 years is rarely reported (22) .
According to our calculations, screening for pheochromocytomas should start at birth. Case reports have been published that describe symptomatic pheochromocytomas before the age of 5 years (23, 24) . All these findings support the current hypothesis that symptomatic bilateral pheochromocytoma can actually develop in utero (24, 25) . Moreover, screening for pheochromocytomas using blood and urine analysis is patient friendly, sensitive, and relatively cheap (19, 20, 25) .
Current VHL guidelines advise lifelong surveillance for all VHL-related manifestations. In our study, we also calculated the age after which probability of future development of a first VHLrelated manifestation is <5%. This could be used as the age to stop surveillance. This is especially of interest for the first-degree relatives of VHL mutation carriers with unknown VHL gene status who are receiving full VHL surveillance and for carriers with unknown phenotype. Additionally, many carriers of type 2c VHL disease would benefit from a defined age to safely stop retinal, cerebellar, spinal cord, kidney, and pancreatic surveillance. Our calculated age to stop surveillance for individuals at risk for VHL phenotype 1 or 2a/b is 34 years. Individuals at risk for VHL phenotype 2c require lifelong surveillance for pheochromocytoma. We observed that after 34 years of age, the probability of detecting a first VHL-related manifestation is <5%, e.g., at the age of 34 years, more than 95% of VHL patients has developed one or more VHL-related manifestations, suggesting that loss of heterozygosity (LOH) occurs at a young age, after which tumours grow and become detectable. The young age of pheochromocytoma onset indicates the oncogenic dominant function of the VHL gene (26) . Causes of LOH of the VHL gene can be either mutation or methylation of the second allele (27) (28) (29) (30) (31) . Moreover, recent studies have shown that mutations or 6 methylation of other vulnerable (flanking) genes also affect the VHL phenotype (32, 33) . If future research can shed light on the genotype-phenotype correlation, then an international analysis of a large cohort could establish more individualized surveillance guidelines. Current surveillance schedules are the same for all VHL phenotypes. Reducing the surveillance for RCC in VHL mutation carriers with a low risk for RCC was recently suggested (34) .
In our study, we focused on defining the probability of detecting organ involvement instead of malignancy. In general, the therapeutic consequences of diagnosing a malignant tumour differ from the consequences of diagnosing a cyst (35) (36) (37) . However, in organs such as the kidney, complex cysts in VHL-related disease can be difficult to distinguish from solid malignancies.
Moreover, transition from cysts to carcinoma can occur (38) (39) (40) .
We conclude that the age to start surveillance for VHL-related manifestations should be revised.
Based on our calculations, several modifications of current VHL surveillance guidelines can be recommended. Most importantly, surveillance for pheochromocytoma should start at a very young age (in the first year of life), and ophthalmologist consultations for retinal angioma screening should be postponed until the age of 7 years. Further prospective studies are necessary, especially in other geographical populations, before incorporating our findings into guidelines and clinical practice. 
